ES2650247T3 - Procedimiento de preparación del bosentán - Google Patents

Procedimiento de preparación del bosentán Download PDF

Info

Publication number
ES2650247T3
ES2650247T3 ES09709282.9T ES09709282T ES2650247T3 ES 2650247 T3 ES2650247 T3 ES 2650247T3 ES 09709282 T ES09709282 T ES 09709282T ES 2650247 T3 ES2650247 T3 ES 2650247T3
Authority
ES
Spain
Prior art keywords
bosentan
preparation procedure
formula
compound
structural unit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09709282.9T
Other languages
English (en)
Spanish (es)
Inventor
Abhay Gaitonde
Bindu Manojkumar
Sandeep Mekde
Vikas Padalkar
Hemant Mande
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generics UK Ltd
Original Assignee
Generics UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40467334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2650247(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Generics UK Ltd filed Critical Generics UK Ltd
Application granted granted Critical
Publication of ES2650247T3 publication Critical patent/ES2650247T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES09709282.9T 2008-02-08 2009-02-06 Procedimiento de preparación del bosentán Active ES2650247T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
INKA02282008 2008-02-08
IN228KO2008 2008-02-08
PCT/GB2009/050120 WO2009098517A1 (en) 2008-02-08 2009-02-06 Process for preparing bosentan

Publications (1)

Publication Number Publication Date
ES2650247T3 true ES2650247T3 (es) 2018-01-17

Family

ID=40467334

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09709282.9T Active ES2650247T3 (es) 2008-02-08 2009-02-06 Procedimiento de preparación del bosentán

Country Status (10)

Country Link
US (1) US8785461B2 (cg-RX-API-DMAC10.html)
EP (1) EP2245018B1 (cg-RX-API-DMAC10.html)
JP (1) JP5683276B2 (cg-RX-API-DMAC10.html)
CN (1) CN101939301B (cg-RX-API-DMAC10.html)
AU (1) AU2009211159B2 (cg-RX-API-DMAC10.html)
CA (1) CA2712860C (cg-RX-API-DMAC10.html)
ES (1) ES2650247T3 (cg-RX-API-DMAC10.html)
NZ (1) NZ587793A (cg-RX-API-DMAC10.html)
PT (1) PT2245018T (cg-RX-API-DMAC10.html)
WO (1) WO2009098517A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009004374A1 (en) 2007-06-29 2009-01-08 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
US8530488B2 (en) 2007-10-24 2013-09-10 Generics [Uk] Limited Crystalline forms of bosentan
JP2012507497A (ja) 2008-11-03 2012-03-29 ジェネリクス・（ユーケー）・リミテッド ボセンタンおよび関連物質のｈｐｌｃ分析方法、ならびに参照スタンダードまたはマーカーとしてのこれら物質の使用
WO2013098577A1 (en) * 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of bosentan
CN104487057A (zh) * 2012-05-11 2015-04-01 韩诺生物制药株式会社 波生坦控释口服制剂
CN112457259B (zh) * 2020-12-08 2024-02-20 重庆康乐制药有限公司 一种磺胺多辛的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5739333A (en) * 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
US6136971A (en) * 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
SI1535613T1 (sl) 1999-11-17 2010-12-31 Teva Pharma Postopek za pripravo polimorfne oblike atorvastatin kalcija
HUP0204069A3 (en) 1999-12-16 2005-01-28 Teva Pharma Novel processes for making- and a new crystalline form of- leflunomide and pharmaceutical composition containing it
PT1254121E (pt) 2000-01-25 2006-06-30 Hoffmann La Roche Preparacao de sulfonamidas
US6479692B1 (en) 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
AU2003209669A1 (en) 2003-02-25 2004-09-17 Hetero Drugs Limited Amorphous form of losartan potassium
US7872019B2 (en) 2003-03-12 2011-01-18 Cadila Healthcare Limited Polymorphs and amorphous form of (S)-(+)-clopidogrel bisulfate
WO2004087660A1 (en) 2003-04-02 2004-10-14 Hetero Drugs Limited A novel process for amorphous form of donepezil hydrochloride
AU2006248593B2 (en) 2005-05-17 2011-03-17 Actelion Pharmaceuticals Ltd. Dispersible bosertan tablet
US20080188663A1 (en) 2007-01-29 2008-08-07 Ashok Kumar Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I
BRPI0809171A2 (pt) 2007-04-02 2014-09-16 Auspex Pharmaceuticals Inc "composto, composição farmacêutica, método para tratamento,prevençõ ou melhora de um ou mais , sintomas de uma desordem mediada pela endotelina em um sujeito, método de inibição de ligação d euma endotelina a um receptor eta ou etb e método para modular a atividade mediada pelo receptor de endotelina"
WO2008135795A2 (en) 2007-05-08 2008-11-13 Generics [Uk] Limited Polymorphic forms of bosentan
WO2009004374A1 (en) 2007-06-29 2009-01-08 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
EP2205591A1 (en) 2007-10-11 2010-07-14 Actavis Group PTC EHF Novel polymorphs of bosentan
US8530488B2 (en) 2007-10-24 2013-09-10 Generics [Uk] Limited Crystalline forms of bosentan
ATE530531T1 (de) * 2007-12-18 2011-11-15 Dipharma Francis Srl Verfahren zur herstellung von bosentan
WO2009095933A2 (en) 2008-01-10 2009-08-06 Msn Laboratories Limited Improved and novel process for the preparation of bosentan
US20110021547A1 (en) 2008-01-24 2011-01-27 Actavis Group Ptc Ehf Substantially Pure and a Stable Crystalline Form of Bosentan
WO2009112954A2 (en) 2008-03-13 2009-09-17 Actavis Group Ptc Ehf Processes for the preparation of bosentan and related compounds using novel intermediates
WO2009141167A1 (en) * 2008-05-23 2009-11-26 Synthon B.V. Bosentan salts
JP2012507497A (ja) 2008-11-03 2012-03-29 ジェネリクス・（ユーケー）・リミテッド ボセンタンおよび関連物質のｈｐｌｃ分析方法、ならびに参照スタンダードまたはマーカーとしてのこれら物質の使用
IT1393136B1 (it) 2009-03-11 2012-04-11 Sifa Vitor S R L Procedimento per la preparazione del bosentan

Also Published As

Publication number Publication date
CN101939301B (zh) 2016-07-06
CN101939301A (zh) 2011-01-05
CA2712860A1 (en) 2009-08-13
AU2009211159A1 (en) 2009-08-13
US20110039871A1 (en) 2011-02-17
EP2245018A1 (en) 2010-11-03
PT2245018T (pt) 2017-12-05
CA2712860C (en) 2014-11-18
JP2011511054A (ja) 2011-04-07
NZ587793A (en) 2012-06-29
EP2245018B1 (en) 2017-08-30
AU2009211159B2 (en) 2013-02-07
US8785461B2 (en) 2014-07-22
WO2009098517A1 (en) 2009-08-13
JP5683276B2 (ja) 2015-03-11

Similar Documents

Publication Publication Date Title
ES2634490T3 (es) Derivados de ácido napht-2-ylacetico para tratar el sida
ES2637287T3 (es) Cerámica
ES2525481T3 (es) Derivados espirocíclicos de ácido tetrónico
ES2544974T3 (es) Base, productos que contienen la misma, métodos de preparación y usos de los mismos
AR112532A2 (es) Compuestos de tetraciclina sustituidos con flúor en c7
ES2485825T3 (es) Intermedio de rosuvastatina cálcica y método de preparación del mismo
CL2011002115A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 5-fenil-pirazin-2-ona, inhibidores de la tirosina-quinasa de bruton (btk); proceso de preparación de los compuestos, compuesto intermediario, composición farmacéutica y uso en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
CL2009002201A1 (es) Procedimiento de sintesis de ivabradina por aminacion reductiva y posterior resolucion optica; y uno de los compuestos intermediarios considerados.
CU24354B1 (es) Procedimiento de obtención de derivados de tetrafluoropropilmorfolina
UY32062A (es) Inhibidores de beta-secretasa
PE20141174A1 (es) Compuestos de pirrol como inhibidores de la bomba de protones
HRP20120129T8 (en) Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
NI200900151A (es) Nuevo procedimiento de síntesis de la agomelatina.
GEP20125512B (en) Process for synthesis of agomelatin
CL2007001784A1 (es) Compuestos derivados de benzoxazol de formula la, su composicion farmaceutica, metodo para medir in vivo depositos de amoloide empleando dicha composicion, y uso del compuesto la para preparar un medicamento, y compuesto de formula ib, y su uso como precursor en la preparacion de un compuesto marcado.
MX2013006179A (es) Proceso para la preparacion de 2-metoximetil-1,4-bencenodiamina, sus derivados y sales de esta.
PA8840901A1 (es) Nuevo procedimiento de resolución de enantiómeros de (3,4-dimetoxi-biciclo[4.2.0]octa-1,3,5-trien-7-il, aplicación en la sistesis de ivabradina
ES2585077T3 (es) Procedimientos para la preparación de 6-cloro-2,3,4,9-tetrahidro-1H-carbazol-1-carboxamida y de sus precursores
MA33027B1 (fr) Nouveau procede de synthese de l'ivabradine zet de ses sels d'addition a un acide pharmaceutiquement acceptable
CL2011000296A1 (es) Proceso de preparación del ester metílico del ácido 4-oxo-octahidro-indol-1-carboxílico y compuestos intermediarios utilizados.
ES2655265T3 (es) Procedimiento de preparación de bifenilanilidas sustituidas
PT2462098E (pt) Processos para a preparação de derivados de ácido 1-(2- halobifenil-4-il)-ciclopropanocarboxílico
ES2508117T3 (es) Uso del butanoato de 4-[etil(dimetil)amonio)] en el tratamiento de la enfermedad cardiovascular
EA201200498A1 (ru) Новый способ синтеза ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
CO6341474A2 (es) Formas solidas de (1r,2s,3r)-1-(2-isoxazol-3-il)-1h-imidazol-4-il) butano-1,2,3,4-tetraol y metodos para su uso